NICE Endorses Eladynos for Post-Menopausal Bone Disease
The National Institute for Health Care and Research has endorsed Theramex’s Eladynos (abaloparatide) as a new treatment option for postmenopausal bone disease. Scheduled to be available on the NHS in England within three months, this new drug is anticipated to benefit over 14,000 individuals in the UK who are at a very high risk of fractures due to osteoporosis following menopause.
Osteoporosis is a condition that affects 3.8 million people in the UK. It is characterized by a reduction in bone mineral density and bone mass, or alterations in the quality or structure of the bone, leading to weakened bones and an increased risk of fractures. The disease predominantly impacts older women post-menopause. During menopause, the levels of estrogen—a crucial hormone for maintaining bone density and strength—drop significantly, resulting in reduced bone density and a higher likelihood of fractures.
Current treatments for osteoporosis include bisphosphonates such as alendronic acid and ibandronic acid, Eli Lilly’s selective estrogen receptor modulator Evista (raloxifene), parathyroid hormone treatments like teriparatide, and biological drugs including Amgen’s Prolia (denosumab) and Amgen/UCB’s Evenity (romosozumab). However, these treatments may not be suitable or effective for all patients.
NICE's decision to approve Eladynos was influenced by patient testimonies describing the debilitating nature of osteoporosis and the profound impact it has on daily life, affecting both mental and physical health. Eladynos is designed to enhance bone density by stimulating bone-forming cells while also reducing the risk of fractures. This provides a valuable alternative for those who have not responded to or cannot tolerate the conventional treatment options.
Eladynos is not only clinically effective but also cost-effective. The drug is administered via a pre-filled pen that delivers the medication through an injection into the muscle. This user-friendly delivery method is likely to be appreciated by patients seeking a straightforward treatment regimen.
In related developments, Bayer announced in March the positive outcomes from the late-stage OASIS 3 study, which supports the use of its experimental non-hormonal menopause drug, elinzanetant, for treating moderate-to-severe vasomotor symptoms (VMS) like hot flashes, experienced by up to 80% of women during menopause.
Additionally, a study published in April in Neurology by Canadian researchers found a connection between early menopause, a heightened risk of cardiovascular disease, and cognitive decline later in life.
These advancements in medical research and drug development underscore the ongoing efforts to enhance the quality of life for women experiencing menopause and its associated complications. Eladynos represents a significant step forward in the management of osteoporosis, promising to offer relief and improved bone health for thousands of women in the UK.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
